Key Points Archer Aviation is attempting to build an air taxi service. The stock has been highly volatile, with deep drawdowns a fairly common experience. 10 stocks we like better than Archer Aviation › Archer Aviation (NYSE: ACHR) makes an electric vertical lift aircraft called Midnight. The company is in the process of getting Midnight approved as an effective air taxi. It is an exciting concept...
Key Points Archer Aviation is attempting to build an air taxi service. The stock has been highly volatile, with deep drawdowns a fairly common experience. 10 stocks we like better than Archer Aviation › Archer Aviation (NYSE: ACHR) makes an electric vertical lift aircraft called Midnight. The company is in the process of getting Midnight approved as an effective air taxi. It is an exciting concept and could create an entirely new market within the aerospace industry. But investors need to go into this stock with their eyes wide open. Here's what you need to know. About Archer Aviation's plunge Archer Aviation's stock hit an all-time high of just over $13 per share in late 2025. It has since lost around half of its value. Not a lot has changed about the business during this stock downturn, which highlights the fact that emotions and news flow are the key drivers of the stock price right now. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » In fact, deep drawdowns aren't new for this upstart aerospace business. The current drop isn't even the deepest one investors have suffered. At one point a few years ago, the stock lost over 80% of its value. This is hardly surprising given that the company is unprofitable and unlikely to become sustainably profitable for a while longer as it spends heavily to build its business. A rebound isn't out of the cards, but it would be a big move That said, Wall Street's emotions can swing quickly and dramatically. It is entirely possible that Archer Aviation's stock price could rebound toward its all-time highs when the company carries its first commercial customers. The hope is that this will take place in 2026 in Abu Dhabi. However, even that will just be one step in a much longer journey. So investors should probably tread with caution even if the stock rebounds in t...
Chevron (NYSE: CVX) and ExxonMobil (NYSE: XOM) are often compared to one another, and for good reason: They are two of the largest integrated energy companies in the world, and they are both based out of the United States. Right now, Exxon's stock has been outdistancing Chevron's shares. But over the long-term, dividend investors shouldn't lose faith in Chevron's future just because of one relativ...
Chevron (NYSE: CVX) and ExxonMobil (NYSE: XOM) are often compared to one another, and for good reason: They are two of the largest integrated energy companies in the world, and they are both based out of the United States. Right now, Exxon's stock has been outdistancing Chevron's shares. But over the long-term, dividend investors shouldn't lose faith in Chevron's future just because of one relatively short stretch of trouble. Chevron is falling behind Through the first five-and-half months or so of 2024, Exxon's stock price has increased by around 17%. Chevron's stock has risen less than half of that figure, at roughly 7%. Both stocks have been tracking Brent crude prices higher, but it is pretty clear that Exxon has been the bigger beneficiary of Wall Street's enthusiasm for the energy sector. One notable reason for that has virtually nothing to do with oil prices. Chevron is working to acquire smaller peer Hess (NYSE: HES). However, the deal has run into a big problem: Exxon. Hess and Exxon are partners on an important oil project. Exxon believes it has the right to buy Hess out of the project if Hess itself gets bought, but that would make buying Hess a lot less desirable for Chevron. This could drag the proposed deal out or, perhaps, even lead to the acquisition getting scuttled. Interestingly enough, Exxon just bought smaller peer Pioneer Natural Resources. That deal wasn't being contested by anyone and was consummated fairly quickly. The benefit of the acquisition is that Exxon has grown its resource base while Chevron is, basically, being stymied from doing the same thing with its own energy portfolio. Investors are likely worried that Chevron's production growth will fall behind that of its most relevant peer. The next year could be filled with headline risk for Chevron, and all of its efforts to buy Hess could, in the end, be for naught. Chevron's future isn't a one-year story That said, investors need to understand that Chevron doesn't really need Hess. It...
Groupon GRPN posted earnings of 17 cents per share for the fourth quarter of 2025, in line with the Zacks Consensus Estimate. The company had reported a loss of $1.2 per share in the year-ago quarter. Revenues of $132.71 million missed the Zacks Consensus Estimate by 3.25%. The figure increased 2% on a year-over-year basis (flat on an FX-neutral basis). The top-line growth was supported by continu...
Groupon GRPN posted earnings of 17 cents per share for the fourth quarter of 2025, in line with the Zacks Consensus Estimate. The company had reported a loss of $1.2 per share in the year-ago quarter. Revenues of $132.71 million missed the Zacks Consensus Estimate by 3.25%. The figure increased 2% on a year-over-year basis (flat on an FX-neutral basis). The top-line growth was supported by continued momentum in North America Local, partially offset by Enterprise channel deceleration and underperformance in organic and owned marketing channels Region-wise, North America’s revenues of $98.7 million missed the consensus mark by 6.58% and grew 2.1% year over year. International revenues of $34 million beat the consensus mark by 4.84% and increased 0.9% year over year (declined 6.3% on an FX-neutral basis) Gross billings totaled $446.5 million in the fourth quarter of 2025, reflecting a 4% year-over-year increase (up 2% on an FX-neutral basis). Groupon, Inc. Price, Consensus and EPS Surprise Groupon, Inc. price-consensus-eps-surprise-chart | Groupon, Inc. Quote GRPN’s Quarterly Details Local revenues of $124.5 million missed the Zacks Consensus Estimate by 3.14% and rose 4% year over year. North America Local revenues increased 4% year over year. International Local revenues grew 3.5% year over year (declined 3.7% on an FX-neutral basis). Excluding the Giftcloud divestiture and Italy, International Local revenues increased 9%. Consolidated Travel revenues of $3.76 million missed the consensus mark by 10.26% and declined 13.2% year over year. North America Travel revenues decreased 17.5% year over year. International Travel revenues decreased 5% in the reported quarter (declined 13.1% on an FX-neutral basis). On a consolidated basis, Goods revenues of $4.44 million beat the consensus mark by 4.01% and declined 27.3% year over year. North America Goods revenues declined 39.9%, and International Goods revenues decreased 17.8% year over year (24.7% excluding the foreign exch...
Campbell's Soup Company is a high-yielding stock in 2026, as its share price plunges into deep value territory. Analysts say reduce, but institutions accumulate
Campbell's Soup Company is a high-yielding stock in 2026, as its share price plunges into deep value territory. Analysts say reduce, but institutions accumulate
In this article NBIS NVDA Follow your favorite stocks CREATE FREE ACCOUNT Jensen Huang, chief executive officer of Nvidia Corp., speaks during the 2026 CES event in Las Vegas, Nevada, US, on Tuesday, Jan. 6, 2026. Siemens and Nvidia announced an expansion of their strategic partnership to develop industrial and physical AI solutions to bring AI-driven innovation to industrial workflow. Photographe...
In this article NBIS NVDA Follow your favorite stocks CREATE FREE ACCOUNT Jensen Huang, chief executive officer of Nvidia Corp., speaks during the 2026 CES event in Las Vegas, Nevada, US, on Tuesday, Jan. 6, 2026. Siemens and Nvidia announced an expansion of their strategic partnership to develop industrial and physical AI solutions to bring AI-driven innovation to industrial workflow. Photographer: Bridget Bennett/Bloomberg via Getty Images Bloomberg | Bloomberg | Getty Images Shares of Nebius Group popped 10% on Wednesday after Nvidia announced it will invest $2 billion in the artificial intelligence cloud company. As part of the deal, the companies will collaborate on AI infrastructure deployment, fleet management, inference and AI factory design and support, according to a release . Nvidia said the investment reflects its confidence in Nebius' business and engineering expertise. "Nebius is building an AI cloud designed for the agentic era, fully integrated from silicon to software and powered by NVIDIA's next-generation accelerated compute," Nvidia CEO Jensen Huang said in a statement. "Together, we are scaling the cloud to meet the surging global demand for intelligence." The announcement comes a week after Nvidia unveiled strategic partnerships with Lumentum and Coherent , investing $2 billion in each company. Nvidia also announced a "significant investment" in Mira Murati's Thinking Machines Lab on Tuesday as part of a new multiyear strategic partnership. Nvidia contributed $30 billion to the $110 billion funding round that OpenAI announced late last month, and it said in November that it planned to invest up to $10 billion in Anthropic. Read more CNBC tech news How the Iran war and rising energy prices are threatening semiconductor demand Kevin Mandia sold his cybersecurity company to Google in 2022. He has a fresh $190 million for a new venture Musk's xAI wants to build a power plant in Mississippi. Regulators planned a key meeting on Election Day, 200 mile...
Anthropic PBC告知一名法官，该公司今年可能损失高达数十亿美元的收入，并敦促法院迅速采取行动，支持其阻止特朗普政府将该公司列为美国供应链风险实体的请求。此前，该公司因人工智能安全问题与美国国防部发生冲突。 在Anthropic就供应链风险认定起诉国防部一天后，这家初创公司在旧金山举行的一场听证会上，向美国地区法官 Rita F. Lin 陈述了事件的紧迫性。双方争议的焦点在于，该公司要求...
Anthropic PBC告知一名法官，该公司今年可能损失高达数十亿美元的收入，并敦促法院迅速采取行动，支持其阻止特朗普政府将该公司列为美国供应链风险实体的请求。此前，该公司因人工智能安全问题与美国国防部发生冲突。 在Anthropic就供应链风险认定起诉国防部一天后，这家初创公司在旧金山举行的一场听证会上，向美国地区法官 Rita F. Lin 陈述了事件的紧迫性。双方争议的焦点在于，该公司要求确保其人工智能不会被用于对美国民众进行大规模监控或部署自主武器。 与此同时，持有OpenAI和Anthropic股份的 微软 公司也提交了自己的陈述书，敦促法官暂时阻止政府的相关举措，因为这些举措可能会推迟美国国防部当前所有“信息技术产品与服务的合同签订工作”。 Anthropic的律师 Michael Mongan 周二辩称，联邦政府的行为已导致超过100家企业客户联系该公司，对继续与Anthropic合作表示疑虑。 他还表示，一家金融服务公司已暂停与Anthropic一份价值5000万美元合同的谈判；一家制药公司要求将合同期限缩短10个月；一家金融科技公司则将其1000万美元的合同缩减至500万美元，“明确将此与”Anthropic和联邦政府之间的纠纷挂钩。蒙根称，Anthropic首席财务官预计，这对公司2026年营收造成的损失总计可能在数亿美元至数十亿美元之间。 针对Anthropic相关请求的听证会原定于4月3日举行，法官已将其提前至3月24日。 蒙根要求联邦政府作出承诺，在下一次听证会前不对Anthropic采取任何报复性行动，例如发布影响这家人工智能初创公司的行政命令。 美国司法部律师 James Harlow 表示：“我不准备就此事作出任何承诺。” Anthropic希望法官撤销其供应链风险认定，并要求美国各机构撤回相关指令。该公司称，自己正因与政府意见相左而被排斥，并表示此案涉及的法律原则，会影响到所有与政府观点相悖的联邦承包商。 上周，美国国防部已正式将其认定结果通知Anthropic。该公司首席执行官 Dario Amodei 随后发表声明称，政府的行为不“具备法律依据”，并表示公司“别无选择，只能通过法庭提出质疑”。 除微软外，Anthropic还获得了科技行业其他机构的支持。 在一封致法官的联名信中，来自OpenAI和 谷歌 的数十名人工智能科学家...
(RTTNews) - CRISPR Therapeutics AG (CRSP), Wednesday announced the pricing of $550 million of its convertible senior notes due 2031 in a private offering to persons reasonably believed to be qualified institutional buyers. Notably, the offering was upsized from the previously announced offering of $350 million aggregate principal amount of notes. Additionally, the company has granted the initial p...
(RTTNews) - CRISPR Therapeutics AG (CRSP), Wednesday announced the pricing of $550 million of its convertible senior notes due 2031 in a private offering to persons reasonably believed to be qualified institutional buyers. Notably, the offering was upsized from the previously announced offering of $350 million aggregate principal amount of notes. Additionally, the company has granted the initial purchasers of the notes an option to purchase upto an additional $50 million aggregate principal amount of the notes. The conversion rate will initially be 13.0617 common shares per $1,000 principal amount of notes, the company noted. The net proceeds from the offering, expected to close on March 16, will be utilized to fund general corporate purposes. In the pre-market hours, CRSP is trading at $52.95, up 0.28 percent on the Nasdaq. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Tredegar press release ( TG ): Q4 Non-GAAP EPS of $0.32. Revenue of $184.07M (+19.5% Y/Y). More on Tredegar Tredegar Trades At A Deep Discount As The Market Tests A Recovery Tredegar: Besides Uncertainty, Expect Nothing More Financial information for Tredegar
Tredegar press release ( TG ): Q4 Non-GAAP EPS of $0.32. Revenue of $184.07M (+19.5% Y/Y). More on Tredegar Tredegar Trades At A Deep Discount As The Market Tests A Recovery Tredegar: Besides Uncertainty, Expect Nothing More Financial information for Tredegar
Rate, review, share on Apple Podcasts and join the conversation on email. On the podcast today: Spurs lose 5-2 away to Atlético. Igor Tudor dropped Guglielmo Vicario only to reintroduce him on 17 minutes after a disastrous start for Spurs and, specifically Antonin Kinsky. The panel as whether that’s it for Igor Tudor and if this has been the worst managerial stint of all time. Elsewhere, late joy ...
Rate, review, share on Apple Podcasts and join the conversation on email. On the podcast today: Spurs lose 5-2 away to Atlético. Igor Tudor dropped Guglielmo Vicario only to reintroduce him on 17 minutes after a disastrous start for Spurs and, specifically Antonin Kinsky. The panel as whether that’s it for Igor Tudor and if this has been the worst managerial stint of all time. Elsewhere, late joy and later heartbreak at St James’ Park. Harvey Barnes looked to have won it until Dani Olmo’s quick feet won a penalty and Lamine Yamal did the rest. Liverpool were welcomed to hell losing 1-0 away at Galatasaray and Bayern Munich are very good aren’t they, Barry? Plus, another missed Panenka in the FA Cup and your questions answered. Support Barry here. You can also find Football Weekly on Instagram, TikTok, and YouTube.
Yau Ming Low/iStock via Getty Images February U.S. Consumer Price Index: +0.3% M/M vs. +0.3% consensus and +0.2% prior, according to data released by the Bureau of Labor Statistics on Wednesday. +2.4% Y/Y vs. +2.4% consensus and +2.4% in January. Core CPI (excludes food and energy): +0.2% M/M vs. +0.2% consensus and +0.3% prior. +2.5% Y/Y vs. +2.5% consensus and +2.5% prior. Developing…. Check bac...
Yau Ming Low/iStock via Getty Images February U.S. Consumer Price Index: +0.3% M/M vs. +0.3% consensus and +0.2% prior, according to data released by the Bureau of Labor Statistics on Wednesday. +2.4% Y/Y vs. +2.4% consensus and +2.4% in January. Core CPI (excludes food and energy): +0.2% M/M vs. +0.2% consensus and +0.3% prior. +2.5% Y/Y vs. +2.5% consensus and +2.5% prior. Developing…. Check back for updates. More on the US Economy Fill Up Your Car, Things Could Get Worse U.S. Dollar Index (DXY): Technical Picture As Inflation And Geopolitical Uncertainty Loom A new demand warning from small businesses Nonfarm payrolls contract in February, hit by healthcare strike; unemployment rate ticks up to 4.4%
hapabapa/iStock Editorial via Getty Images Belgian biopharma company UCB ( UCBJY ) announced on Wednesday that its arthritis therapy Bimzelx outperformed AbbVie’s ( ABBV ) immunology therapy Skyrizi in a head-to-head trial for psoriatic arthritis, an inflammatory condition affecting skin and joints. Citing topline data, UCB ( UCBJF ) stated that its BE BOLD trial achieved the primary endpoint rela...
hapabapa/iStock Editorial via Getty Images Belgian biopharma company UCB ( UCBJY ) announced on Wednesday that its arthritis therapy Bimzelx outperformed AbbVie’s ( ABBV ) immunology therapy Skyrizi in a head-to-head trial for psoriatic arthritis, an inflammatory condition affecting skin and joints. Citing topline data, UCB ( UCBJF ) stated that its BE BOLD trial achieved the primary endpoint related to a clinical measure called ACR50, which measures a 50% or greater improvement in American College of Rheumatology response criteria. Bimzelx indicated superiority compared to Skyrizi in terms of ACR50 with a statistically significant effect over 16 weeks, the company added. BE BOLD, which enrolled more than 500 adults with active psoriatic arthritis, indicated a well-tolerated safety profile for Bimzelx with no new safety signals, according to UCB ( UCBJY ). The parallel group study is the fourth head-to-head study that showed Bimzelx’s superiority in psoriatic disease and the first in PsA. More on AbbVie, UCB SA AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript AbbVie: Stabilizes Near $233 While Testing Resistance AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript Top 10 healthcare stocks with highest dividend yield amid volatile markets AbbVie sees promising early-stage data for weight loss asset ABBV-295
Best Buy (BBY) reported a surprise sales slump in its key holiday shopping season. Same-store sales declined 0.8% in the fourth quarter, the company said Tuesday. Wall Street had hoped for a 0.2% increase after two straight quarters of positive growth. "We continue to see customers who are resilient, but they are definitely deal-focused," Best Buy CEO Corie Barry told Yahoo Finance in a call with ...
Best Buy (BBY) reported a surprise sales slump in its key holiday shopping season. Same-store sales declined 0.8% in the fourth quarter, the company said Tuesday. Wall Street had hoped for a 0.2% increase after two straight quarters of positive growth. "We continue to see customers who are resilient, but they are definitely deal-focused," Best Buy CEO Corie Barry told Yahoo Finance in a call with reporters. Best Buy expects first quarter same-store sales to return to growth, rising 1%. Barry said more than 50% of its customers make more than $100,000 per year. Revenue for the fourth quarter totaled $13.81 billion, less than the $13.88 billion Wall Street had expected, per Bloomberg consensus data. Adjusted earnings per share came in higher at $2.61, more than the $2.46 the Street predicted. Best Buy stock is down more than 30% in the past year, but popped up more than 8% in early trading. For the full year, revenue came in at $41.69 billion, just below the $41.76 billion Wall Street predicted. Adjusted earnings per share came in at $6.43, $0.12 above Wall Street's estimates for $6.31. For the year, same-store sales grew 0.5%, less than the 0.9% increase Wall Street was looking for. For 2027, the company expects revenue to come in the range of $41.2 billion to $42.1 billion, alongside same-store sales that are expected to fall in a range between a 1% decline and 1% rise for the year. Adjusted earnings per share are expected to be in a range of $6.30-$6.60. This year, Best Buy is also watching the rise in memory costs as heightened demand impacts supply. Barry said it's "something our industry has faced in different peaks and valleys relatively often through the past 25 years." She added that the team is pulling in inventory, trying to provide its manufacturers with longer forecast horizons, working to find the right price points for consumers, and educating them on what's available. The team expects strength in computing and mobile phones to continue into 2026, after...